CACLP - The largest IVD Expo & Conference

I-SPY 2 Trial to Evaluate Natera's Signatera for Post-Neoadjuvant Breast Cancer Monitoring

Industry news | 15 September, 2023 | CACLP

Original from: 360DX

 

Natera on Thursday announced a new study within the Phase II I-SPY 2 trial that will evaluate the ability of its Signatera minimal residual disease test to monitor breast cancer patients' response to neoadjuvant therapy.

Signatera is a circulating tumor DNA (ctDNA) test that is customized to detect each patient's unique set of tumor mutations. It can be used to track patients' cancer progression and monitor them for relapse. 

 

In the prospective study, researchers will use the test in real time to monitor 600 patients with breast cancer of any subtype. Natera hopes the research will support efforts to establish ctDNA as a composite clinical trial endpoint and provide additional data on patients' post-surgical ctDNA status after neoadjuvant therapy.

 

Within I-SPY 2, an adaptive trial of neoadjuvant breast cancer therapies sponsored and operated by Quantum Leap Healthcare Collaborative, researchers have previously studied Signatera to assess treatment efficacy. The prior retrospective analysis showed that early ctDNA clearance during neoadjuvant chemotherapy was significantly associated with an increased likelihood of achieving pathologic complete response.

 

In a statement, Laura Esserman and Laura van ‘t Veer, professors at the University of California, San Francisco, and principal investigators of the I-SPY trial, noted that this prospective study, combined with the retrospective research, "will help us understand the role that ctDNA can play in decision-making for predicting response and improving our ability to determine who needs less therapy and who needs more."

 

Earlier this year, the Centers for Medicare & Medicaid Services said it would cover Signatera for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer across all subtypes. Other studies of Signatera have found that MRD testing can provide prognostic information and guide treatment decisions in other tumor types, including colorectal and bladder cancer.

Source: I-SPY 2 Trial to Evaluate Natera's Signatera for Post-Neoadjuvant Breast Cancer Monitoring

 

Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference